Journal article
Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
- Abstract:
-
Duration of protection from SARS-CoV-2 infection in people with HIV (PWH) following vaccination is unclear. In a sub-study of the phase 2/3 the COV002 trial (NCT04400838), 54 HIV positive male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells >350 cells/ul) received two doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and MesoScale Discovery (MSD)), neutralisation,...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Bibliographic Details
- Publisher:
- American Society for Clinical Investigation Publisher's website
- Journal:
- JCI Insight Journal website
- Volume:
- 7
- Issue:
- 7
- Article number:
- e157031
- Place of publication:
- United States
- Publication date:
- 2022-02-22
- Acceptance date:
- 2022-02-18
- DOI:
- EISSN:
-
2379-3708
- Pmid:
-
35192543
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1240641
- Local pid:
- pubs:1240641
- Deposit date:
- 2022-03-15
Terms of use
- Copyright holder:
- Ogbe et al.
- Copyright date:
- 2022
- Rights statement:
- ©2022, Ogbe et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record